ORTHO CYCLEN-21
LOE ApproachingNDAORAL-21TABLET
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO CYCLEN-21 is an oral contraceptive tablet containing norgestimate and ethinyl estradiol, approved in 1989 for pregnancy prevention. It is a combined hormonal contraceptive indicated for women of reproductive age seeking reliable birth control. The drug works by suppressing ovulation through hormonal mechanisms.
LOE Approaching
As an oral contraceptive approaching loss of exclusivity with moderate competitive pressure (30%), commercial teams should expect contracting resources and shift toward generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an approaching LOE, ORTHO CYCLEN-21 represents a legacy product with declining career trajectory and limited hiring demand. Professionals working on this brand should position themselves for generic transition roles or migrate to growth-stage contraceptive innovations.
Brand ManagerProduct Manager
Worked on ORTHO CYCLEN-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.